Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cerebral Edema l: Introduction01:19

Cerebral Edema l: Introduction

30
Cerebral edema is a pathological increase in brain water content that disrupts intracranial pressure regulation and impairs neurological function. Because the cranial vault is rigid, even modest increases in tissue volume can compromise cerebral perfusion, distort neural structures, and initiate secondary injury. Cerebral edema develops through four principal mechanisms: vasogenic, cytotoxic, interstitial, and ionic.Vasogenic EdemaVasogenic edema arises from disruption of the blood–brain...
30
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

20
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...
20
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

19
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
19
Physiology of the Genitourinary System III: Urine Concentration and Dilution01:20

Physiology of the Genitourinary System III: Urine Concentration and Dilution

1.5K
The kidneys concentrate or dilute urine to maintain water and electrolyte balance. Nephrons, particularly the loop of Henle, play a crucial role in this process through the countercurrent multiplication system. This system establishes a high osmolarity in the renal medulla, which is essential for water reabsorption. In the loop of Henle’s descending limb, water is reabsorbed into the surrounding medulla due to its permeability to water. In contrast, the ascending limb actively transports...
1.5K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

2.7K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.7K
Urea Cycle01:23

Urea Cycle

44.1K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotics in Cerebrovascular Disease: The Final Frontier.

Missouri medicineยท2026
Same author

Current Concepts in the Management of Cerebral Aneurysms.

Missouri medicineยท2026
Same author

Beyond COSS: The Evolution of Hemodynamic Imaging and Revascularization Strategies in Chronic Cerebrovascular Occlusion.

Missouri medicineยท2026
Same author

The Role of Artificial Intelligence in Acute Ischemic Stroke Care: A Narrative Review.

Missouri medicineยท2026
Same author

Metastatic osteosarcoma to the squamous temporal bone with intra- and extracranial extension: A case report.

Surgical neurology internationalยท2025
Same author

Use of an Expert Panel for Symptomatic Patients With Grade I Degenerative Lumbar Spondylolisthesis: A Randomized Clinical Trial.

Neurosurgeryยท2025

Related Experiment Video

Updated: May 1, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.4K

The history of urea as a hyperosmolar agent to decrease brain swelling.

Balint Otvos1, Varun R Kshettry, Edward C Benzel

  • 1Cleveland Clinic Lerner College of Medicine; and.

Neurosurgical Focus
|April 2, 2014
PubMed
Summary
This summary is machine-generated.

Early hyperosmolar agents like urea were used to reduce brain swelling and intracranial pressure. Mannitol eventually replaced urea due to a better side effect profile, advancing cerebral edema management.

More Related Videos

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics
08:43

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics

Published on: November 30, 2012

19.8K
Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

60.0K

Related Experiment Videos

Last Updated: May 1, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.4K
Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics
08:43

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics

Published on: November 30, 2012

19.8K
Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

60.0K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Intracranial pressure management is critical in neurocritical care.
  • Hyperosmolar agents aim to reduce brain volume and intracranial pressure.

Observation:

  • Intravascular osmolar shifts were observed to affect cerebrospinal fluid (CSF) dynamics in 1919.
  • Urea was the first hyperosmolar agent widely used for reducing brain swelling starting in 1950.

Findings:

  • Urea demonstrated efficacy but was associated with significant side effects, including coagulopathy and rebound hypertension.
  • Mannitol, introduced in 1961, offered a comparable or superior alternative with a better safety profile.
  • Mannitol replaced urea as the preferred hyperosmolar agent by the late 1960s/early 1970s.

Implications:

  • The historical use of urea and its subsequent replacement by mannitol significantly advanced the understanding of cerebral edema.
  • This evolution in hyperosmolar therapy established foundational strategies for managing intracranial pressure and brain volume.